All
MARIPOSA Trial to Examine How Amivantamab Plus Lazertinib Compares With Osimertinib in EGFR+ NSCLC
February 24th 2022The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.
AON Collaborates With VieCure to Advance Adoption of Precision Oncology and Personalized Cancer Care
February 23rd 2022The collaboration between AON and VieCure is designed to facilitate the delivery of precision oncology and personalized care and treatment for patients across the ever-expanding AON network.
Key Objectives With Selpercatinib Use in RET Fusion-Positive Thyroid Cancer
February 22nd 2022Vivek Subbiah discusses the phase 1/2 LIBRETTO-001 study which sought to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors.
FDA Grants Priority Review to Liso-Cel for Adults With Relapsed/Refractory LBCL
February 17th 2022The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.